Advances in prevention and diagnosis of hepatocellular carcinoma

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 3, 2008, Pages 425-433

  Spangenberg, Hans Christian ^a   Thimme, Robert ^a   Blum, Hubert E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute liver disease; Chronic liver disease; Imaging analysis; Liver transplantation; Therapy; Tumor marker; Vaccination

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; ESTROGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IODINATED POPPYSEED OIL; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; POLYPRENOIC ACID; PROTEINASE INHIBITOR; RIBAVIRIN;

CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MALIGNANT TRANSFORMATION; MORBIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY PREVENTION; PROTEOMICS; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 55349143826     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.3.425     Document Type: Review

References (84)

1. Okuda K. Hepatocellular carcinoma. J. Hepatol. 32(Suppl. 1), 225-237 (2000).
2. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35(3), 421-430 (2001).
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35 (3), 519-524 (2002).
4. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122(6), 1609-1619 (2002).
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003).
6. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10(2 Suppl. 1), S115-S120 (2004).
7. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S179-S188 (2004).
8. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127(5 Suppl. 1), S17-S26 (2004).
9. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5 Suppl. 1), S27-S34 (2004).
10. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1), S35-S50 (2004).
11. Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: conference proceedings. Hepatology 40(6), 1465-1473 (2004).
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005).
13. Marrero JA. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 22(3), 248-253 (2006).
14. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007).
15. Kulik LM. Advancements in hepatocellular carcinoma. Curr. Opin. Gastroenterol. 23(3), 268-274 (2007).
16. Taylor-Robinson SD, Foster GR, Arora S et al. Increase in primary liver cancer in the UK, 1979-1994. Lancet 350, 1142-1143 (1997).
17. Deuffic S, Poynard T, Buffat L et al. Trends in primary liver cancer. Lancet 351, 214-215 (1998).
18. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745-750 (1999).
19. El-Serag HB, Davila JA, Petersen NJ et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139(10), 817-823 (2003).
20. Capocaccia R, Sant M, Berrino F et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th Century. Am. J. Gastroenterol. 102(8), 1661-1670 (2007).
21. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348(17), 1625-1638 (2003).
22. Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37(3), 520-527 (2003).
23. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347(3), 168-174 (2002).
24. Sun HC, Zhang W, Qin LX et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J. Hepatol. 47(5), 684-690 (2007).
25. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
26. Yano Y, Yamashita F, Sumie S et al. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am. J. Gastroenterol. 97(1), 156-161 (2002).
27. Pollicino T, Squadrito G, Cerenzia G et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126(1), 102-110 (2004).
28. Bruno S, Crosignani A, Maisonneuve P et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46(5), 1350-1356 (2007).
29. Akuta N, Suzuki F, Kawamura Y et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46(5), 1357-1364 (2007),
30. Ming L, Thorgeirsson SS, Gail MH et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36(5), 1214-1220 (2002).
31. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S72-S78 (2004).
32. Hassan MM, Hwang LY, Hatten CJ et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36(5), 1206-1213 (2002).
33. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97(12), 3036-3043 (2003).
34. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S87-S96 (2004).
35. Marrero JA, Fontana RJ, Fu S et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J. Hepatol. 42(2), 218-224 (2005).
36. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126(2), 460-468 (2004).
37. Caldwell SH, Crespo DM, Kang HS et al. Obesity and hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S97-S103 (2004).
38. Bravi F, Bosetti C, Tavani A et al. Coffee drinking and hepatocellular carcinoma risk a meta-analysis. Hepatology 46(2), 430-435 (2007).
39. Nangler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834), 121-124 (2007).
40. Dufour JF, Huber O, Kozrna SC et al. Tumour suppressors in liver carcinogenesis. J. Hepatol. 47(6), 860-867 (2007).
41. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin. Liver Dis. 19(3), 235-242 (1999).
42. Sudawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin. Liver Dis. 24(1), 77-88 (2004).
43. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40(2), 276-283 (2004).
44. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127(5 Suppl. 1), S56-S61 (2004).
45. Calvisi DF, Ladu S, Gorden A et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 117(9), 2713-2722 (2007).
46. Nakamoto Y, Guidotti L, Kuhlen C et al. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341-350 (1998).
47. Sakamoto Y, Kaneko S, Fan H et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J. Exp. Med. 196(8), 1105-1111 (2002).
48. Pikarsky E, Porat RM, Stein I et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007), 461-466 (2004).
49. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 431 (7007), 405-406 (2004).
50. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 36(5), 1046-1049 (2002).
51. Talwalkar JA, Cores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S126-S132 (2004).
52. Tateishi R, Shiina S, Yoshida H et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44(6), 1518-1527 (2006).
53. Kim J, Ki SS, Lee SD et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 101(9), 2051-2059 (2006).
54. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19(2), 71-77 (2005).
55. Capurro M, Wanless IR, Sherman M et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1), 89-97 (2003).
56. Llovet JM, Chen Y, Wurmbach E et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131(6), 1758-1767 (2006).
57. Kandil D, Leiman G, Allegretta M et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer 111(5), 316-322 (2007).
58. Di Bisceglie AM. Screening for hepatocellular carcinoma: being old is not all bad. Am. J. Gastroenterol. 99(8), 1477-1478 (2004).
59. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4), 918-928 (1985).
60. Leung TW, Tang AM, Zee B et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94(6), 1760-1769 (2002).
61. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19(3), 329-338 (1999).
62. Farinati F, Rinaldi M, Gianni S et al. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 89(11), 2266-2273 (2000).
63. Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellutar carcinoma: the JIS score compared with the CI4P score. Hepatology 40(6), 1396-1405 (2004).
64. Chevret S, Trinchet JC, Mathieu D et al.; Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J. Hepatol. 31 (1), 133-141 (1999).
65. Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41 (4), 707-716 (2005).
66. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4), 1005-1014 (2004).
67. El-Serag HB, Siegel AB, Davila JA et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J. Hepatol. 44(1), 158-166 (2006).
68. Yamauchi N, Watanabe A, Hishinuma M et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod. Pathol. 18(12), 1591-1598 (2005).
69. Libbrecht L, Severi T, Cassiman D et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol. (11), 1405-1411 (2006).
70. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group [see comments]. N. Engl. J. Med. 336(26), 1855-1859 (1997).
71. Folgori A, Capone S, Ruggeti L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190-197 (2006).
72. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45(3), 579-587 (2007).
73. Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147(10), 677-684 (2007).
74. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351(15), 1521-1531 (2004).
75. Koike Y, Shiratori Y, Sato S et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 32(6), 1216-1223 (2000).
76. Sala M, Fuster J, Llovet JM et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 10(10), 1294-1300 (2004).
77. Muto Y, Moriwaki H, Ninomiya M et al.; Hepatoma Prevention Study Group. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med. 334(24), 1561-1567 (1996).
78. Kubo S., Nishiguchi S, Hirohashi K et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 134(10), 963-967 (2001).
79. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32(2), 228-232 (2000).
80. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232), 802-807 (2000).
81. Lau WY, Leung TW, Ho SK et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353(9155), 797-801 (1999).
82. Boucher E, Corbinais S, Rolland Y et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38(5), 1237-1241 (2003).
83. Ren ZG, Lin ZY, Xia JL et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J. Gastroenterol. 10(19), 2791-2794 (2004).
84. Kaposi-Novak P, Lee JS, Gomez-Quiroz L et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116(6), 1582-1595 (2006).